ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 3)

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL).

New combination therapies provide new ways to manage patients with CLL and may affect the duration of treatment and reduce the development of drug resistance. There is reference to a recent study of ABT-199 plus rituximab.

Year of Production:
Running Time:


Comments are closed.